Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Patient reported swallowing outcomes after prophylactic versus reactive gastrostomy during chemoradiotherapy for head and neck cancer: Results from the SwallPEG randomized trial.

Created on 29 Oct 2026

Authors

Tatiana Dragan, Frédéric Duprez, Antoine Digonnet, Sofiana Mootassim-Billah, André Van Gossum, Yassine Lalami, Vincent Vakaet, Maurine Salmon, Marianne Paesmans, Dirk Van Gestel

Published in

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. Pages 111835. Oct 28, 2026. Epub Oct 28, 2026.

Abstract

To compare prophylactic (p-) versus reactive (r-) percutaneous endoscopic gastrostomy (PEG) placement during definitive chemoradiotherapy (CRT) for locally advanced, nonmetastatic head and neck carcinoma, with swallowing-related quality of life (QoL) as the primary endpoint.
SwallPEG is a prospective, multicenter, randomized phase III trial of patients undergoing definitive cisplatin-based CRT. Patients were randomized 1:1 to pPEG before CRT or rPEG based on predefined nutritional criteria. All received standardized nutritional counseling, weekly dietitian assessment, and swallowing rehabilitation. The primary endpoint was swallowing-related QoL at 6 months, assessed using the MD Anderson Dysphagia Inventory (MDADI) composite score. Secondary endpoints included nutritional outcomes, treatment-related toxicity, PEG-related complications, and early oncologic outcomes.
Fifty-seven patients were analyzed (pPEG, n = 28; rPEG, n = 29). Following a prespecified interim analysis that reached the futility boundary, the trial was closed early in the context of slow accrual. Median MDADI composite scores at 6 months were 69.5 (Q1-Q3, 60.0-80.0) and 74.7 (Q1-Q3, 58.9-87.9), respectively (P = 0.595). Swallowing function declined during CRT and subsequently recovered without a significant between-group difference. Weight loss at 6 months was comparable (-7.0 % vs - 9.0 %; P = 0.67). No significant differences were observed in treatment-related toxicity, PEG-related complications, chemotherapy delivery, or early oncologic outcomes.
No difference in swallowing-related QoL was demonstrated between (p-) and rPEG strategies. Although interpretation is limited by early trial closure and reduced sample size, the findings support individualized PEG placement based on clinical need.

PMID:
42951256
Bibliographic data and abstract were imported from PubMed on 29 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement